EUVIMEDEUVIMED entdecken
Crossref

Single intravenous and oral dose pharmacokinetics of the antiseizure medication brivaracetam in healthy cats

Tom Jukier iD, Chu Zhang iD, Robert D Arnold iD, Amanda Gross iD

Journal of Veterinary Pharmacology and Therapeutics · 2024

DOI: 10.1111/jvp.13473 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Veterinary Pharmacology and Therapeutics, 2024. Verfasst von Tom Jukier und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Sciences, College of Veterinary Medicine, Auburn University, Auburn, Alabama, USA. Hauptthemen laut MEDLINE: Pyrrolidinones, Anticonvulsants, Cross-Over Studies, Area Under Curve. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: EveryCat Health Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The number of available antiseizure medications with demonstrated efficacy in cats is limited. As such, there is a need to evaluate the pharmacokinetics of newer medications so that proper dosing regimens can be made. Brivaracetam (BRV) is a more potent analogue of levetiracetam, and is Food and Drug Administration approved for use in people. The goal of this study was to describe the pharmacokinetics of intravenous and oral doses of BRV in healthy cats. A cross‐over study involving eight healthy cats, that were administered 10 mg of BRV intravenously as a bolus and orally in the fasted state. Blood samples were collected over 24 h. Analysis was performed using liquid chromatography‐mass spectrometry. Data were subjected to non‐compartmental analysis. Median (min–max) of maximal concentration, time to maximal concentration, area under the curve, elimination half‐life and oral absolute bioavailability were 902 (682–1036) ng/mL, 0.6 (0.5–2.0) h, 6.4 (5.2–7.2) h, 8145 (6669–9351) ng × h/mL and 100% (85–110) respectively. BRV appeared to be well tolerated by all cats. A single dose of BRV is well tolerated both orally and intravenously. Maximal concentrations are produced rapidly and within the human reference interval considered to be therapeutic.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyrrolidinonesAnticonvulsantsCross-Over StudiesArea Under CurveAnimalsCatsAdministration, OralMaleFemaleHalf-LifeInjections, IntravenousBiological AvailabilityAdministration, Intravenous

Stichwörter der Autor:innen

brivaracetamcatepilepsyfelineseizure

Substanzen

PyrrolidinonesbrivaracetamAnticonvulsants

Autor:innen und Institutionen

  • Department of Clinical Sciences, College of Veterinary Medicine, Auburn University, Auburn, Alabama, USA.
  • Drug Discovery and Development Research, Harrison College of Pharmacy, Auburn University, Auburn, Alabama, USA.
  • Scott-Ritchey Research Center, College of Veterinary Medicine, Auburn University, Auburn, Alabama, USA.

ORCID-Profile: Tom Jukier, Chu Zhang, Robert D Arnold, Amanda Gross

Förderung

  • EveryCat Health Foundation

Zitieren

APA

Jukier, T., Zhang, C., Arnold, R. D., & Gross, A. (2024). Single intravenous and oral dose pharmacokinetics of the antiseizure medication brivaracetam in healthy cats. Journal of Veterinary Pharmacology and Therapeutics. https://doi.org/10.1111/jvp.13473

Vancouver

Jukier T, Zhang C, Arnold RD, Gross A. Single intravenous and oral dose pharmacokinetics of the antiseizure medication brivaracetam in healthy cats. Journal of Veterinary Pharmacology and Therapeutics. 2024. doi:10.1111/jvp.13473

BibTeX
@article{Jukier2024,
  author = {Jukier, Tom and Zhang, Chu and Arnold, Robert D and Gross, Amanda},
  title = {Single intravenous and oral dose pharmacokinetics of the antiseizure medication brivaracetam in healthy cats},
  journal = {Journal of Veterinary Pharmacology and Therapeutics},
  year = {2024},
  doi = {10.1111/jvp.13473}
}
Kostenlos starten →